论文部分内容阅读
本科自1990年5月～1995年10月,用表阿霉素、卡铂、V_P-16治疗14例肺癌合并上腔静脉综合征患者,现将结果分析如下。 1 临床资料 1.1 一般资料:本组14例,男性9例,女性5例。年龄43～71岁。右侧肺癌10例:中心型9例,周围型1例;左侧肺癌4例,均为中心型。病理类型:小细胞肺癌8例,鳞癌3例,腺癌3例。根据UICC新的肺癌分期标准Ⅲa期4例,其中T_3N_2M_02例,T_2N_2M_02例;Ⅲb期4例,其中T_4N_3M_01例,T_3N_3M_03例;Ⅳ期6例,其中T_3N_3M_13例,T_2N_2M_1 1例,T_4N_2M_1 2例。根据Soler分级上腔静脉综合征Ⅱ度7例,Ⅲ度7例。全身状况Karmofaskg记分均在50分以上。所有
Undergraduate from May 1990 to October 1995, with epirubicin, carboplatin, V_P-16 treatment of 14 patients with lung cancer complicated with superior vena cava syndrome, the results are as follows. 1 Clinical data 1.1 General Information: The group of 14 patients, 9 males and 5 females. Age 43 ~ 71 years old. Right lung cancer in 10 cases: 9 cases of central type, peripheral type in 1 case; 4 cases of left lung cancer, are central. Pathological types: small cell lung cancer in 8 cases, squamous cell carcinoma in 3 cases, adenocarcinoma in 3 cases. According to UICC new lung cancer staging criteria Ⅲa 4 cases, including T_3N_2M_02 cases, T_2N_2M_02 cases; Ⅲb 4 cases, including T_4N_3M_01 cases, T_3N_3M_03 cases; Ⅳ stage 6 cases, including T_3N_3M_13 cases, T_2N_2M_1 cases, T_4N_2M_1 2 cases. According to Soler classification of superior vena cava syndrome in 7 cases, Ⅲ degree in 7 cases. Karmofaskg overall condition scores were above 50 points. all